China Securities News Agency, March 6, Asymchem Laboratories (Tianjin) Co.Ltd(002821) announced that in order to promote the strategic layout of the company’s overall industrial development and further improve the service capacity of the company’s emerging business sector, the company signed an investment agreement with Shanghai Industrial Comprehensive Development Zone Co., Ltd. on March 4, 2022, and the company invested in the newly established wholly-owned subsidiary, It is planned to invest and build a biological drug cdmo R & D and commercial production base in Fengxian, Shanghai with its own or self raised funds of 3 billion yuan. The project is planned to be designed as a whole, constructed by stages and put into operation in batches.
© China Stock Market News